<DOC>
	<DOCNO>NCT02074514</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy , safety , tolerability sofosbuvir ( SOF ) + ribavirin ( RBV ) treatment-naive adult chronic genotype 1 3 hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Safety Efficacy Sofosbuvir Plus Ribavirin Treatment-Naive Adults With Chronic Genotype 1 3 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>HCV RNA â‰¥10^4 IU/mL screen Confirmed chronic HCV genotype 1 3 infection HCV treatment naive Approximately 30 % individual may compensate cirrhosis screen Any chronic liver disease Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Current prior history clinical hepatic decompensation Contraindication RBV therapy , e.g. , history clinically significant hemoglobinopathy ( sickle cell disease , thalassemia ) . Chronic use systemically administer immunosuppressive agent History solid organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>